1887

Abstract

Newcastle disease virus (NDV) is being developed as an oncolytic virus for virotherapy. In this study we analysed the regulation of complement-mediated inactivation of a recombinant NDV in different host cells. NDV grown in human cells was less sensitive to complement-mediated virus inactivation than NDV grown in embryonated chicken eggs. Additionally, NDV produced from HeLa-S3 cells is more resistant to complement than NDV from 293F cells, which correlated with higher expression and incorporation of complement regulatory proteins (CD46, CD55 and CD59) into virions from HeLa-S3 cells. Further analysis of the recombinant NDVs individually expressing the three CD molecules showed that CD55 is the most potent in counteracting complement-mediated virus inactivation. The results provide important information on selecting NDV manufacture substrate to mitigate complement-mediated virus inactivation.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000498
2016-08-01
2022-01-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/8/1765.html?itemId=/content/journal/jgv/10.1099/jgv.0.000498&mimeType=html&fmt=ahah

References

  1. Biswas M., Johnson J. B., Kumar S. R., Parks G. D., Elankumarana S. 2012; Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J Virol 86:12708–12716 [View Article][PubMed]
    [Google Scholar]
  2. Blue C. E., Spiller O. B., Blackbourn D. J. 2004; The relevance of complement to virus biology. Virology 319:176–184 [View Article][PubMed]
    [Google Scholar]
  3. Buijs P. R., Verhagen J. H., van Eijck C. H., van den Hoogen B. G. 2015; Oncolytic viruses: from bench to bedside with a focus on safety. Hum Vaccin Immunother 11:1573–1584 [View Article][PubMed]
    [Google Scholar]
  4. Cassel W. A., Garrett R. E. 1965; Newcastle disease virus as an antineoplastic agent. Cancer 18:863–868[PubMed] [CrossRef]
    [Google Scholar]
  5. Cassel W. A., Murray D. R. 1992; A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9:169–171[PubMed]
    [Google Scholar]
  6. Cheng X., Wang W., Xu Q., Harper J., Carroll D., Galinski M. S., Suzich J., Jin H. 2016; Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 90:5343–5352 [View Article][PubMed]
    [Google Scholar]
  7. Chiocca E. A., Rabkin S. D. 2014; Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300 [View Article][PubMed]
    [Google Scholar]
  8. Cooper N. R. 1991; Complement evasion strategies of microorganisms. Immunol Today 12:327–331 [View Article][PubMed]
    [Google Scholar]
  9. Coyne K. E., Hall S. E., Thompson S., Arce M. A., Kinoshita T., Fujita T., Anstee D. J., Rosse W., Lublin D. M. 1992; Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 149:2906–2913[PubMed]
    [Google Scholar]
  10. Cummings K. L., Waggoner S. N., Tacke R., Hahn Y. S. 2007; Role of complement in immune regulation and its exploitation by virus. Viral Immunol 20:505–524 [View Article][PubMed]
    [Google Scholar]
  11. Huang Z., Panda A., Elankumaran S., Govindarajan D., Rockemann D. D., Samal S. K. 2004; The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol 78:4176–4184[PubMed] [CrossRef]
    [Google Scholar]
  12. Iwata K., Seya T., Yanagi Y., Pesando J. M., Johnson P. M., Okabe M., Ueda S., Ariga H., Nagasawa S. 1995; Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46. J Biol Chem 270:15148–15152[PubMed] [CrossRef]
    [Google Scholar]
  13. Janeway C. A Jr, Travers P., Walport M., Shlomchik M. J. 2001; The immune system in health and disease. Immunobiology, 5th edn. New York: Garland Science;
    [Google Scholar]
  14. Johnson J. B., Lyles D. S., Alexander-Miller M. A., Parks G. D. 2012; Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol 86:9929–9940 [View Article][PubMed]
    [Google Scholar]
  15. Laliberte J. P., McGinnes L. W., Peeples M. E., Morrison T. G. 2006; Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles. J Virol 80:10652–10662 [View Article][PubMed]
    [Google Scholar]
  16. Lambris J. D., Ricklin D., Geisbrecht B. V. 2008; Complement evasion by human pathogens. Nat Rev Microbiol 6:132–142 [View Article][PubMed]
    [Google Scholar]
  17. Li L., Spendlove I., Morgan J., Durrant L. G. 2001; CD55 is over-expressed in the tumour environment. Br J Cancer 84:80–86 [View Article][PubMed]
    [Google Scholar]
  18. Liszewski M. K., Leung M. K., Atkinson J. P. 1998; Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J Immuno 161:3711–3718
    [Google Scholar]
  19. Liszewski M. K., Fang C. J., Atkinson J. P. 2008; Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 26 Suppl 8:122–127 [View Article][PubMed]
    [Google Scholar]
  20. Markiewski M. M., DeAngelis R. A., Benencia F., Ricklin-Lichtsteiner S. K., Koutoulaki A., Gerard C., Coukos G., Lambris J. D. 2008; Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235 [View Article][PubMed]
    [Google Scholar]
  21. Mazumdar B., Kim H., Meyer K., Bose S. K., Di Bisceglie A. M., Ray R. B., Diamond M. S., Atkinson J. P., Ray R. 2013; Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 87:7902–7910 [View Article][PubMed]
    [Google Scholar]
  22. Moore A. E., Diamond L. C., Mackay H. H., Sabachewsky L. 1952; Influence of hemagglutinating viruses on tumor cell suspensions. II. Newcastle disease virus and Ehrlich carcinoma. Proc Soc Exp Biol Med 81:498–501[PubMed] [CrossRef]
    [Google Scholar]
  23. Murray K. P., Mathure S., Kaul R., Khan S., Carson L. F., Twiggs L. B., Martens M. G., Kaul A. 2000; Expression of complement regulatory proteins – CD 35, CD 46, CD 55, and CD 59 – in benign and malignant endometrial tissue. Gynecol Oncol 76:176–182 [View Article][PubMed]
    [Google Scholar]
  24. Osuka F., Endo Y., Higuchi M., Suzuki H., Shio Y., Fujiu K., Kanno R., Oishi A., Terashima M. et al. 2006; Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. Genomics 88:316–322 [View Article][PubMed]
    [Google Scholar]
  25. Post T. W., Liszewski M. K., Adams E. M., Tedja I., Miller E. A., Atkinson J. P. 1991; Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 174:93–102[PubMed] [CrossRef]
    [Google Scholar]
  26. Prince A. M., Ginsberg H. S. 1957a; Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus–cell interaction. J Immunol 79:94–106
    [Google Scholar]
  27. Prince A. M., Ginsberg H. S. 1957b; Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. II. The mechanism and significance of in vitro recovery from the effect of NDV. J Immunol 79:107–112
    [Google Scholar]
  28. Ren X., Xue C., Kong Q., Zhang C., Bi Y., Cao Y. 2012; Proteomic analysis of purified Newcastle disease virus particles. Proteome Sci 10:32 [View Article][PubMed]
    [Google Scholar]
  29. Ricklin D., Hajishengallis G., Yang K., Lambris J. D. 2010; Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785–797 [View Article][PubMed]
    [Google Scholar]
  30. Rushmere N. K., Knowlden J. M., Gee J. M., Harper M. E., Robertson J. F., Morgan B. P., Nicholson R. I. 2004; Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108:930–936 [View Article][PubMed]
    [Google Scholar]
  31. Russell S. M., Sparrow R. L., McKenzie I. F., Purcell D. F. 1992; Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur J Immunol 22:1513–1518 [View Article][PubMed]
    [Google Scholar]
  32. Saifuddin M., Hedayati T., Atkinson J. P., Holguin M. H., Parker C. J., Spear G. T. 1997; Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78:1907–1911 [View Article][PubMed]
    [Google Scholar]
  33. Simon H. G., Risse B., Jost M., Oppenheimer S., Kari C., Rodeck U. 1996; Identification of differentially expressed messenger RNAs in human melanocytes and melanoma cells. Cancer Res 56:3112–3117[PubMed]
    [Google Scholar]
  34. Spear G. T., Lurain N. S., Parker C. J., Ghassemi M., Payne G. H., Saifuddin M. 1995; Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155:4376–4381[PubMed]
    [Google Scholar]
  35. Stoermer K. A., Morrison T. E. 2011; Complement and viral pathogenesis. Virology 411:362–373 [View Article][PubMed]
    [Google Scholar]
  36. Vanderplasschen A., Mathew E., Hollinshead M., Sim R. B., Smith G. L. 1998; Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 95:7544–7549[PubMed] [CrossRef]
    [Google Scholar]
  37. Varela J. C., Atkinson C., Woolson R., Keane T. E., Tomlinson S. 2008; Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer 123:1357–1363 [View Article][PubMed]
    [Google Scholar]
  38. Zamarin D., Palese P. 2012; Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7:347–367 [View Article][PubMed]
    [Google Scholar]
  39. Zipfel P. F., Skerka C. 2009; Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729–740 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000498
Loading
/content/journal/jgv/10.1099/jgv.0.000498
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error